Does Elotuzumab Improve PFS in High-Risk Myeloma?
The addition of the anti-SLAMF7 antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and maintenance did not improve outcomes for patients with previously...
How Do Patients With Myeloproliferative Neoplasms Fare After COVID-19 Infection?
Two analyses from the MPN-COVID study from a group of researchers led by Tiziano Barbui, MD, of the United Hospitals of Bergamo in Italy,...
Examining Outcomes Among Hispanic Patients With Multiple Myeloma
Hispanic and non-Hispanic Black patients with multiple myeloma (MM) more often present with disease at a younger age and with significant renal dysfunction. These...
DDAVP Prevents Post-Intervention Bleeding Complications in Patients With Low von Willebrand Factor Levels
A recent study suggests 1-desamino-8-D-arginine vasopressin (DDAVP) prevents bleeding in patients with low von Willebrand factor (VWF) levels undergoing major and minor elective procedures....
Can Adding Lenalidomide to Rituximab-MiniCHOP Improve Survival in Older Patients With Diffuse Large B-Cell...
In a phase III trial of patients age 80 or older with diffuse large B-cell lymphoma (DLBCL), attempts to improve on the standard approach...
Predicting CAR T-Cell Treatment Failure in Patients With Aggressive B-Cell Lymphomas
Nearly one-half of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are treated with chimeric antigen receptor (CAR) T-cell therapy experience a relapse...
Moving Beyond Gene Rearrangements to Define High-Risk Diffuse Large B-Cell Lymphoma
In diffuse large B-cell lymphoma (DLBCL), patients typically are risk-stratified according to cell-of-origin, but recent genetics-based classifications led the World Health Organization to establish...
Pegcetacoplan Improves Hematologic Response in PNH Treated With Eculizumab
For patients with paroxysmal nocturnal hemoglobinuria (PNH) who are receiving eculizumab yet have residual anemia, treatment with pegcetacoplan led to broad hemolysis control and...
What Is the Best Method for Cytoreduction in Patients With Acute Myeloid Leukemia and...
In patients with acute myeloid leukemia (AML), hyperleukocytosis is associated with the oncologic emergency leukostasis as well as inferior outcomes, but there are few...
BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma
The combination of once-weekly selinexor with bortezomib and dexamethasone (SVd) demonstrated a 30% reduction in the risk of disease progression or death, compared with...
Current Issue
April 2021 Volume 7 Issue 5
This issue examines long-haul COVID-19, central nervous system relapse in non-Hodgkin lymphoma, and more.